Harvard Medical School & Dana-Farber Cancer Institute
Boston, MA

Dr. Lee M. Nadler is the Virginia and D.K. Ludwig Professor for Cancer Research and Teaching, the dean for Clinical and Translational Research, and the director of Harvard Catalyst at Harvard Medical School. Dr. Nadler is also the senior vice president for Academic Integration and the Pan Mass Challenge Senior Investigator at the Dana-Farber Cancer Institute.

He is renowned his discovery of several important B cell molecules, which established our understanding of human B-cell differentiation and enabled doctors to classify B-cell cancers. His discovery of CD20 also led to the FDA-approved antibody rituximab which has significantly benefited leukemia and lymphoma patients. Among his honors are the 2002 Joseph H. Burchenal Clinical Research Award from the American Association for Cancer Research and election to the Association of American Physicians. Dr. Nadler has been a member of CRI’s Scientific Advisory Council since 1994.

Hodgkin’s [lymphoma] went from a murderer, to now pretty much everyone’s cured.
Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.